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PresentPurpose: To assess locoregional outcomes of inflammatory breast cancer (IBC) patients who received standard
fractionation radiation with daily skin bolus and taxanes as part of combined-modality therapy (CMT).
Methods and Materials: We retrospectively reviewed the charts of 107 patients diagnosed with IBC between
January 1995 and March 2006 who presented to our department for adjuvant radiation therapy (RT).
Results: All patients received chemotherapy (95% anthracycline and 95% taxane), modified radical mastectomy,
and RT to the chest wall and regional lymphatics using standard fractionation to 50 Gy and daily skin bolus. The
RT to the chest wall was delivered via electrons (55%) or photons (45%) in daily fractions of 180 cGy (73%) or 200
cGy (27%). Scar boost was performed in 11%. A majority (84%) of patients completed the prescribed treatment.
Median follow-up was 47 months (range, 10–134 months). Locoregional control (LRC) at 3 years and 5 years was
90% and 87%, respectively. Distant metastases–free survival (DMFS) at 3 years and 5 years was 61% and 47%,
respectively.
Conclusions: Excellent locoregional control was observed in this population of IBC patients who received standard
fractionation radiation with daily skin bolus and taxanes as part of combined-modality therapy. Distant metasta-
ses–free survival remains a significant therapeutic challenge.  2010 Elsevier Inc.
Radiation, Inflammatory breast cancer, Combined modality treatment, Standard fractionation, Taxanes.
Open access under CC BY-NC-ND license. INTRODUCTION
Inflammatory breast cancer (IBC) is a unique entity com-
pared to other non-inflammatory locally advanced breast
cancers. The term ‘‘inflammatory’’ was first coined at Memo-
rial Hospital by Lee and Tannenbaum in 1924 (1). Clinically
IBC is diagnosed by erythema, edema, and induration devel-
oping in the breast over a rapid time course, and pathologi-
cally, widespread tumor emboli invading the dermal
lymphatic system may be observed (2). The condition of
IBC exhibits a tendency for early recurrence (3) and inferior
prognosis (4, 5). Historically, outcomes with radiation and
surgery alone were poor (6). Since the incorporation of neo-
adjuvant (NA) chemotherapy into treatment over the past
several decades, a significant proportion of patients have
demonstrated long-term survival (7).
Neoadjuvant chemotherapy in the management of IBC has
been refined over the past decade. Anthracyclines have been
shown to improve outcomes and are considered part of
standard induction treatment for IBC (8, 9). The Nationalt requests to: Shari Damast, M.D., Department of Radia-
ology, Memorial Sloan-Kettering Cancer Center, New
10065. Tel: (212) 639-6828; Fax: (212) 639-2417;
amasts@mskcc.org
ed in part as a poster at the 50th Annual Meeting of the
1105Surgical Adjuvant Breast and Bowel Project (NSABP)
B-27 trial demonstrated that the addition of preoperative tax-
anes to anthracyclines improves response in operable breast
cancer (10), and the Cancer and Leukemia Group B
(CALGB) Trial 9741 showed that a dose-dense schedule of
chemotherapy administration improves survival in breast
cancer patients with node-positive disease (11). These studies
have indirectly contributed to the incorporation of taxanes
and dose-dense chemotherapy schedules into combined
modality therapy (CMT) for IBC. Several studies have inves-
tigated the impact of these agents on survival outcomes in
specific IBC populations (12–15).
When integrated with NA chemotherapy, both mastec-
tomy and radiation therapy (RT) continue to have an impor-
tant role in the locoregional management of IBC (16, 17).
Given the rarity of the diagnosis, which represents fewer
than 5% of newly diagnosed breast cancers (18), there are
no randomized trials delineating optimal radiation regimens
for this disease. Various single institutions have publishedAmerican Society of Therapeutic Radiology and Oncology, Boston,
MA, September 21–25, 2008.
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Table 1. Patient characteristics
Age (y) 50 (26–81)
Menopausal status
Peri 7 (7%)
Pre 46 (43%)
Post 54 (50%)
Race/ethnicity
African American 13 (12%)
Asian/Pacific Islander 4 (4%)
Caucasian 84 (79%)
Hispanic 3 (3%)
Other 3 (3%)
Skin punch biopsy
Positive 55 (51%)
Negative 15 (14%)
Did not receive 37 (35%)
Hormone receptor status
ER + 59 (55%)
PR + 36 (34%)
Her2 overexpression 40 (37%)
Her 2 status unknown 11 (10%)
Nodes positive (pathologic)
0 23 (22%)
1–3 20 (19%)
4–9 37 (35%)
$10 27 (25%)
Nodes evaluated 16 (0–49)
Nodal ratio
>50% 37 (35%)
<50% 70 (65%)
Laterality
Left 49 (46%)
Right 58 (54%)
Positive/close margins 13 (12%)
Margin status unknown 7 (7%)
Clinical response*
At least partial response to chemotherapy 96 (90%)
Less than partial response 5 (5%)
Pathologic response*
pCR in the axillary lymph nodes 23 (23%)
pCR in the breast 15 (15%)
2002 AJCC Stage (clinical)
NX 6 (6%)
IIIB 94 (88%)
IIIC 7 (6%)
Abbreviation: pCR = pathologic complete response.
Characteristics are given as median (range) for continuous vari-
ables and n (%) for categorical variables.
* Includes only those patients who received NA chemotherapy.
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part of CMT (19–22), and 5-year locoregional control rates
in these studies range from 78% to 92%. These studies, how-
ever, vary in sequencing of radiation (pre vs. post mastec-
tomy), total dose (50–66 Gy), and fractionation schedules
(once daily vs twice daily), making it challenging to draw
definitive conclusions regarding radiation techniques. In
addition, the use of taxanes, now common for IBC, was
incorporated in only small proportions of the study popula-
tions, ranging from 4% to 40% (20–22). There is a paucity
of data on the appropriate radiation regimen in an IBC pop-
ulation who largely receive taxane-containing regimens.
At our institution, over the past decade, IBC patients have
been treated in a consistent fashion with anthracycline and
taxane-containing chemotherapy, modified radical mastec-
tomy (MRM), and locoregional radiation. This purpose of
this study was to examine locoregional outcomes resulting
from our technique using standard fractionation radiation to
50 Gy with daily skin bolus, a considerably lower radiation
dose compared with other regimens recently reported. In
addition, the use of daily skin bolus with no modification
by skin reaction at our institution is considered aggressive.
We therefore also aimed to assess toxicities and tolerability
of this regimen among this specific population.
METHODS AND MATERIALS
Patient selection
The charts of patients diagnosed with IBC between January 1995
and March 2006 were retrospectively evaluated. Only patients irra-
diated in our department with curative intent were included. Patients
with metastatic disease or disease recurrence before RT were
excluded. Patients with a pathologic finding of tumor emboli invad-
ing the dermal lymphatics in their mastectomy specimen but who
lacked clinical findings of IBC were excluded as well. Of 359 charts
reviewed, 107 patients were identified who met these criteria,
including 1 patient with synchronous bilateral IBC.
The majority of patients received their mastectomy and chemo-
therapy treatments at Memorial Sloan-Kettering Cancer Center
(MSKCC). The diagnosis of IBCwas made at the time of initial con-
sultation, generally by an MSKCC surgeon or medical oncologist.
Several patients were diagnosed and initially treated with chemo-
therapy and/or mastectomy at an outside institution before receiving
radiation in our department. The diagnosis of IBC in these cases was
made based on review of the patient’s history, pathology findings,
and outside physician documentation. All pathologic specimens
were reviewed by the MSKCC pathology department confirming
the diagnosis of invasive carcinoma. A skin biopsy (to assess the
presence of tumor emboli in the dermal lymphatics) was performed
in 65% of the study population.
Patient and tumor characteristics are listed in Table 1.
Systemic therapies
The sequencing of chemotherapy, MRM, and RT is outlined in
Fig. 1.
The majority of patients (95%) received anthracycline and tax-
ane-containing chemotherapy. The various regimens administered
are shown in Table 2. The AC-T regimen (doxorubicin (A)
(60 mg/m2) and cyclophosphamide (C) (600 mg/m2) 4 cycles, fol-
lowed by paclitaxel (T) (175mg/m2) 4 cycles) was most common.Before 2004, T was usually administered in the adjuvant setting
after MRM, and after 2004, all of the chemotherapy, including T,
was usually administered neoadjuvantly. Furthermore, after 2004,
the majority of patients received neoadjuvant dose-dense (dd) che-
motherapy, that is, AC-T chemotherapy delivered every 2 weeks
rather than every 3 weeks. For the purpose of analysis, only patients
who received all planned cycles of dd AC-T in the absence of other
chemotherapeutic agents were classified as the ‘‘dose-dense’’ group.
Eleven patients received less common chemotherapy regimens
categorized as ‘‘other’’ in Table 2. The regimens listed as ‘‘other’’
included: dd AC-T with gemcitabine; dd AC-T with gemcitabine
and capecitabine; dd AC followed by weekly paclitaxel; dd AC
followed by docetaxel; paclitaxel alone; docetaxel and cyclo-
phosphamide; docetaxel followed by capecitabine; paclitaxel
followed by cyclophosphamide, epirubicin, and 5-fluorouracil;
Fig. 1. Treatment groups.
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with paclitaxel. One patient with initially chemo-refractory disease
received doxorubicin and vinorelbine, then vinblastine, cyclo-
phosphamide, and doxorubicin, then gemcitabine, epirubicin, and
docetaxel.
Clinical response to chemotherapy was documented by the med-
ical oncologist and surgeon before mastectomy. The majority of
patients achieved at least a partial response determined by clinical
examination. Only 5 patients had less than a partial response (2Table 2. Systemic treatment characteristics
Chemotherapy
AC-T 71 (66%)
Q3 weeks 34 (32%)
Q2 weeks 37 (34%)
A-T-C 7 (7%)
TAC 6 (6%)
EC-T 5 (5%)
A-CMF 4 (4%)
CAF-T 3 (3%)
Other 11 (10%)
Hormonal therapy
Tamoxifen only 13 (12%)
AI only 17 (16%)
Sequential tamoxifen + AI 22 (20%)
Other 7 (7%)
None 48 (45%)
Trastuzumab 13 (12%)
Abbreviations: AC-T = doxorubicin/cyclophosphamide followed
by paclitaxel; A-CMF = doxorubicin followed by cyclophos-
phamide/methotrexate/5-fluorouracil; AI = aromatase inhibitor;
A-T-C = doxorubicin followed by paclitaxel followed by cyclophos-
phamide; CAF-T = cyclophosphamide/doxorubicin/5-fluorouracil
followed by paclitaxel; EC-T = epirubicin/cyclophosphamide fol-
lowed by paclitaxel; TAC = docetaxel/doxorubicin/cyclophospha-
mide.patients, no clear clinical evidence of response; 3 patients, local
progression of clinical signs and symptoms during chemotherapy).
No patient who developed distant metastases while undergoing che-
motherapy was included in this study.Surgery
All patients were treated with MRM. Of the patients, 94 (88%)
had their surgeries performed at MSKCC. Six patients had immedi-
ate breast reconstruction, 3 of these at an outside institution. The
3 patients who received breast reconstruction at MSKCC had com-
plete clinical response to chemotherapy documented by the surgeon
at the time of the operation.
Pathologic complete response (pCR) in the breast indicated the
absence of any tumor cells in the removed breast. We defined
pCR in the axillary lymph nodes (pCR in the nodes) as no residual
microscopic or macroscopic disease in the lymph nodes, indepen-
dent of disease status of the breast. The percentages of patients
achieving pCR are listed in Table 1.
Any patient who developed distant metastases or local progres-
sion after surgery and before RT was excluded.Radiation technique for chest wall and regional lymphatics
The median time from surgery to RT was 137 days (range, 110–
192 days) for the 57 patients who received adjuvant chemotherapy
(Fig. 1, Groups B and D), and 50 days (range, 39–66) for the 50
patients who did not receive adjuvant chemotherapy (Fig. 1, Groups
A and C).
Radiation therapy was delivered to an unreconstructed chest wall
(CW) in 100 patients, to an intact (premastectomy) breast in 1 pa-
tient, and to a reconstructed breast in 6 patients. The target volume
included the entire CW and the draining regional lymphatics. The
median dose to the CW was 5040 cGy (range, 1080–5040 cGy).
Skin bolus (0.5–1.0 cm) was applied daily to the entire CW to ensure
adequate coverage of the skin by the prescription isodose line. Bolus
remained on the skin for the entirety of RT. Boosting the
Table 3. Radiation therapy (RT) treatment characteristics of
study patients
RT duration (days) 39 (34–64)
Regional lymphatic groups targeted
Supraclavicular nodes 107 (100%)
Internal mammary nodes 65 (61%)
Axilla (posterior axillary boost) 29 (27%)
Scar boost performed 12 (11%)
Fraction size (cGy)
180 78 (73%)
200 29 (27%)
Electrons/photons
Electrons 59 (55%)
Photons 44 (41%)
Electrons + photons 4 (4%)
Characteristics are given as median (range) for continuous vari-
ables and n (%) for categorical variables.
Fig. 2. Overall survival: at 3 years, 82%; at 5 years, 61%.
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characteristics are further detailed in Table 3.
The use of electrons rather than photons to treat the CW depended
on patient anatomy, physician discretion, and available technology
of the time, including the availability of CT-simulation, which
became routine at MSKCC in April 1998. Our technique for post-
mastectomy CT-based electron beam radiotherapy has been
described in detail previously (23).
The electron-based CW technique always included the internal
mammary nodes (IMNs) in the target volume. The IMNs were not
always targeted in the photon-based CW technique, and their inclu-
sion depended on the clinical judgment of the treating physician.
When the IMNs were included in a photon CW plan, one of two
techniques was used. Either a separate en face electron beam was
added or, alternatively, the photon tangential fields were widened
to incorporate the IMNs in the first four intercostal spaces.
Patients who experienced progression during RTwere included in
the analysis.Statistical methods
Time to locoregional recurrence (LRR), distant failure, first fail-
ure, and overall survival (OS) were estimated using Kaplan-Meier
methods. All times were estimated from the date of diagnosis,
except for the analysis of response to neoadjuvant chemotherapy,
which was estimated at the date of surgery, when pathologic
response was assessed. For locoregional and distant failure, patients
who died without a recurrence were censored at the time of death,
and patients who were alive and free of each specific recurrence
were censored at last follow-up. Cox proportional hazards regres-
sion was used to assess associations between time to LRR and var-
ious clinical and treatment characteristics. Fisher’s exact test was
used to assess relationships among these characteristics.Fig. 3. Local recurrence–free survival: at 3 years, 90%; at 5 years,
87%.RESULTS
Survival analysis
The median follow-up for survivors was 3.8 years (range,
1.2–11.0 years). Results are shown in Figs. 2 to 5. Four
patients had disease progression while undergoing radiation
(2 local, 2 distant). Patients who failed during the course of
RT were included in the survival analysis and were censored
at the time of first failure or death.In total, 12 patients developed LRR, defined as patholog-
ically confirmed recurrences in the ipsilateral CW and/or
regional lymph nodes either during, or after the completion
of radiation. Seven patients had failures isolated to the skin
or CW, and 4 patients had regional nodal failures (1 supracla-
vicular, 1 axilla, 2 IMNs). One patient had experienced fail-
ure in both the CW and ipsilateral supraclavicular nodal
region.
Unadjusted hazard ratios for the impact of clinical and
treatment characteristics on LRR are shown in Table 4. As
there were only 12 locoregional failures recorded, a multivar-
iate analysis was not performed. Number of positive axillary
lymph nodes and pathologic nodal ratio (NR) greater than 0.5
were significant variables (p < 0.05). Kaplan-Meier analysis
of LRR-free survival according to NR is shown in Fig. 6. A
value of NR > 0.5 was also predictive of distant metastases–
free survival (DMFS) (Fig. 7, p < 0.05), but not OS (p > 0.05).
Preoperative taxanes use was associated with a lower like-
lihood of NR > 0.5. Of the 61 patients who received taxane
Fig. 4. Distant metastases–free survival: at 3 years, 61%; at 5 years,
47%.
Table 4. Unadjusted analysis of time to local failure among
study patients
Characteristic Hazard ratio (95% CI) p Value
Menopausal status
Post Ref NS
Pre 0.81 (0.26–2.6)
Margin status
Positive Ref NS
Negative 0.38 (0.10–1.4)
Clinical N-stage*
IIIB Ref NS
IIIC 1.52 (0.20–11.9)
Nodes positive
0 Ref NS
1–3 1.1 (0.04–17.2)
4–9 2.6 (0.29–23.1)
$10 5.1 (0.61–42.1)
>50% Nodes positive
No Ref 0.04
Yes 3.5 (1.05–11.6)
Nodes positive (continuous) 11.4 (1.9–67.8) 0.008
Fraction size
180 Ref NS
200 0.28 (0.04–2.2)
Electrons/photons
Electrons only Ref NS
Photons 1.12 (0.36–3.5)
Duration of RT
#39 Days Ref NS
>39 Days 1.26 (0.40–4.0)
Time from surgery to RT
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of the 46 patients who did not receive preoperative taxanes (p
< 0.05). Despite this finding, preoperative taxane use was not
a significant predictor for LRR, as shown in Table 4.
No patient who received dose-dense chemotherapy or
a scar boost experienced LRR. Therefore, hazard ratios
were not calculated for these factors. The use of dose-dense
chemotherapy did not significantly affect DMFS or OS.#6 Months Ref NS
>6 Months 2.54 (0.76–8.5)
Response to neoadjuvant chemoy
ALN pCR
No Ref NS
Yes 0.79 (0.10–6.2)
Breast pCR
No Ref NS
Yes 0.32 (0.04–2.5)
Preoperative taxanez
Yes Ref NS
No 0.90 (0.28–2.9)
Abbreviations:Chemo = chemotherapy; CI = confidence interval;
pCR = pathologic complete response; NS = not significant; RT =Toxicity
All patients developed acute dermatitis (88% experienced
a Grade 2 or higher skin reaction). Of the patients, 68%
developed moist desquamation (Grade 2–3) during RT.
Bolus on the skin was maintained throughout treatment as
tolerable. Treatment breaks were discouraged but necessary
in some circumstances because of skin toxicity.
Eleven patients received less than prescription dose to the
CW secondary to intolerable moist desquamation. In this
group, the median dose to the CW was 4,800 cGy (range,
3,800–4,980 cGy), with only 1 patient receiving less thanFig. 5. Disease-free survival: At 3 years, 54%; at 5 years, 40%.
radiation therapy.
* Excludes the 6 patients who were Stage NX.
y Taken from date of surgery, after response to chemotherapy was
assessed, includes only those patients who received neoadjuvant
chemotherapy (n = 101).
z Excludes 5 patients who received surgery first and 5 patients
who did not receive taxane.4,600 cGy. Thirteen patients received less than the prescrip-
tion dose to the regional lymph nodes because of acute toxic-
ity with a median dose of 4,680 cGy to the supraclavicular
region (range, 4,500–4,980 cGy). Altogether, 90 patients
(84%) completed treatment to full dose as prescribed. Of
note, no patient who stopped treatment early because of
skin toxicity developed LRR. In all cases, the skin was noted
to have healed in subsequent follow-up visits.
Late toxicities were documented at least 90 days after radi-
ation using the Common Terminology Criteria for Adverse
Fig. 6. Impact of nodal ratio (NR) on locoregional control (LRC). Fig. 7. Impact of nodal ratio (NR) on distant metastases–free sur-
vival (DMFS).
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toxicity; one developed ulceration on the mastectomy scar
(attributed to a recall reaction from taxol), and the other de-
veloped radionecrosis of CW tissues after repeat RT for
CW recurrence. One patient developed radiation pneumonitis
requiring steroids. A total of 33 patients (31%) had docu-
mented lymphedema, resulting either from MRM, RT, or
a combination of the two modalities. Only 2 patients had
edema of the limb with >30% interlimb discrepancy (Grade
3). Subsequent malignancies, including 2 cases of contralat-
eral IBC, occurred in 13 patients.
DISCUSSION
As the incidence of IBC continues to increase (18), the
importance of optimizing both systemic and local therapies
has become paramount. In locally advanced breast cancers,
LRR is a devastating outcome, not only for its negative
impact on quality of life (24) but also for its potential contri-
bution to distant failures and death (25). We examined
locoregional outcomes in a large population of IBC patients
who received standard fractionation RT with daily skin bolus
to 50 Gy in conjunction with contemporary CMT.
We found that this radiation regimen was effective and
generally well tolerated, and that locoregional control
(LRC) at 5 years (87%) was excellent. The disease-free sur-
vival and OS rates were comparable to those reported in other
recent studies (26, 27). Caution must be used in applying
these data to all IBC patients; however, as we excluded
patients with metastatic disease or recurrent disease before
RT. By applying these specific selection criteria, we sought
both to study a homogenous population to provide clinically
meaningful and applicable data and to facilitate comparison
of our results with those of other published studies.
The largest recently published series on IBC comes from
the MD Andersen Cancer Center (MDACC), where IBC
patients have been treated with accelerated hyperfractionated
(twice daily) treatment and with dose escalation (66 Gy) (19,
22). In the most recent MDACC update, Bristol et al.reported 84% LRC at 5 years in patients who completed
CMT (22). The rationale for the use of altered fractionation
is to reduce tumor repopulation and late effects (28). From
a logistical point of view, however, a twice daily schedule
is not practical for patients who travel considerable distances
to receive radiation treatment, and it requires extra resources
in busy radiation centers. Moreover, the superiority of accel-
erated fractionation for IBC has not been established and is
unlikely to be studied in a randomized trial setting, given
the rarity of IBC. In the same update, the authors found an
association between dose escalation and increased risk of
late toxicity including symptomatic lymphedema, brachial
plexopathy, and CW fibrosis. The authors of this study con-
cluded that dose escalation may not benefit all IBC patients
who respond to NA chemotherapy and should be reserved
only for patients with specific high-risk features (22).
Our study suggests that standard fractionation radiation
with daily skin bolus is a reasonable and effective treatment
regimen that may be a substitute to altered fractionation
approaches in certain IBC populations. The locoregional out-
comes we demonstrated were excellent and corroborated the
results reported in the recent MDACC study, as well as other
published studies that used a median dose of 50 to 60 Gy with
daily fractionation for IBC and demonstrated 5-year LRC
rates ranging from 78% to 92% (20, 21, 24, 29, 30). Our
radiation technique differed from those described in previous
studies in several important ways: (1) mastectomy scar boost
was not routinely advocated, and performed in only a small
fraction (11%) of patients (2) skin bolus was used daily to
ensure that the entire surface of the skin was included within
the prescription isodose line; and (3) the CW was most often
treated with electron therapy to minimize the radiation dose
to critical normal structures such as heart and lung.
Nodal status was the one prognostic variable examined
that had a statistically significant impact on LRR. The risk
for LRR appeared to increase with each additional involved
lymph node and was significantly higher in patients with
>50% axillary lymph node involvement at the time of
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may be an important predictor of local and distant recurrence
in patients treated with NA chemotherapy agrees with recent
literature (31, 32). The substantial proportion (35%) of our
IBC cohort with NR > 0.5, even after primary chemotherapy,
highlights the need for improved up-front systemic therapies
targeted for this population.
The majority (95%) of our population received taxanes in
addition to anthracycline-based chemotherapy. We found
that preoperative taxane use was less likely to be associated
with the negative predictor of NR > 0.5. Dose-dense ther-
apy may be beneficial in IBC given the high proliferative
nature of the cancer. A dose-dense regimen of epirubicin
and docetaxel in a recently published Phase II trial for
IBC demonstrated high response rates (15). Interestingly,
in our study, no patient who received dose-dense AC-T che-
motherapy had LRR. Despite this favorable effect, we were
not able to demonstrate a statistically significant impact of
dose-dense AC-T chemotherapy on DMFS or OS. Analysis
of these data is limited, however, because of the retrospec-
tive nature of this study, in which assignment to dose-
dense chemotherapy may have been confounded by other
variables.This study had several limitations. It was a single-armed
retrospective review, and lacked a treatment comparison
group. There were only few locoregional events, thereby
making it difficult to demonstrate many predictors. The
exclusion of all patients who had disease progression before
RT limits the applicability of our study to all IBC patients, as
nearly 25% present initially with distant metastases. The
median follow-up for the group was only 4 years, which is
reasonable, given the overall poor prognosis of the popula-
tion. Nevertheless, longer follow-up would be helpful in
assessing patient outcomes.CONCLUSION
Standard fractionation radiation to 50 Gy with comprehen-
sive nodal radiation and daily skin bolus was an effective and
tolerable regimen for patients with IBC who received CMT
including taxanes. Locoregional outcomes in our cohort of
patients treated with this technique were excellent. Given
the high rate of distant metastases and the aggressive beh-
avior of this disease, further study of systemic agents is
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